Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
Launched by SYLENTIS, S.A. · Mar 24, 2021
Trial Information
Current as of June 12, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject is a male or a female aged ≥ 18 years
- • Have given their written consent to participate in the study
- • Use of artificial tears (AT), autologous serum or specific dry eye medications during the last 6 months prior to the selection
- • Willing to not use AT or autologous serum for the study duration
- • VAS scale for Dry Eye Symptom Score ≥ 40
- • Total CFS ≥ 5
- • Schirmer's test with anesthesia \< 10 mm/5min
- • Patients with Sjögren Syndrome
- Exclusion Criteria:
- • Any concomitant treatment or prior ocular procedure or surgery, or alteration of the dose of systemic medications at the time of entry into the study
- • Use of contact lenses during the study
- • Significant Eye diseases according to investigator's opinion
About Sylentis, S.A.
Sylentis, S.A. is a biotechnology company focused on the development of innovative RNA-based therapeutics for the treatment of prevalent diseases. With a strong commitment to advancing the field of genetic medicine, Sylentis specializes in designing and delivering small interfering RNA (siRNA) treatments that target specific genes involved in various pathologies. The company’s research and clinical initiatives aim to improve patient outcomes through precision medicine, leveraging cutting-edge technologies and a robust pipeline of drug candidates. Sylentis is dedicated to collaboration with academic and industry partners to accelerate the translation of its discoveries into effective therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dothan, Alabama, United States
Scottsdale, Arizona, United States
Glendale, California, United States
Los Angeles, California, United States
Newport Beach, California, United States
Rancho Cordova, California, United States
San Diego, California, United States
Torrance, California, United States
Aurora, Colorado, United States
Colorado Springs, Colorado, United States
Littleton, Colorado, United States
Jacksonville, Florida, United States
Largo, Florida, United States
Miami, Florida, United States
Ormond Beach, Florida, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Morrow, Georgia, United States
Carmel, Indiana, United States
Waltham, Massachusetts, United States
Ypsilanti, Michigan, United States
Kansas City, Missouri, United States
Saint Louis, Missouri, United States
Washington, Missouri, United States
Asheville, North Carolina, United States
High Point, North Carolina, United States
Fargo, North Dakota, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Cranberry Township, Pennsylvania, United States
Rapid City, South Dakota, United States
Memphis, Tennessee, United States
Nashville, Tennessee, United States
El Paso, Texas, United States
Houston, Texas, United States
Falls Church, Virginia, United States
Birmingham, Alabama, United States
Garden Grove, California, United States
Pamplona, Navarra, Spain
Barcelona, , Spain
Madrid, , Spain
Sevilla, , Spain
Valladolid, , Spain
Zaragoza, , Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials